Back

Metabolitin-based molecular drug delivery by targeting GPR158 in glioblastoma

Zhao, H.; Zhu, W.; Li, J.; Lin, J.; Lei, X.; Zhang, P.; Zhang, J.

2021-12-13 cancer biology
10.1101/2021.12.13.472376 bioRxiv
Show abstract

Glioblastoma multiforme (GBM) is a lethal form of intracranial tumor. One of the obstacles to treat GBM is the blood-brain barrier which limit the transportation of drugs into the tumor site. Here, based on our previous study on metabolitin (MTL) and osteocalcin, we generated a molecular drug delivery system that consisted of metabolitin and small molecules such as fluorescent dye or peptide drugs for diagnosis and treatment. And we designed a GBM diagnostic probe (MTL-ICG) and therapeutic peptide drug (MTL-NBD) that can cross the blood-brain barrier (BBB). In a NIR animal live imaging system, we found MTL-ICG can penetrate cross BBB and label the GBM site. The in vitro experiment showed that MTL-NBD had inhibitory effect on GBM cell line (U87-MG). Besides, after orthotopic transplantation of GBM into mouse cortex, treatment of MTL-NBD intravenously showed inhibition trend, which were similar with the effect of NBD, a known anti-tumor polypeptide drug. In addition, we found the GPR158, the receptor of osteocalcin, was also high expressed in grafting site. Taken together, these findings suggest that MTL is a promising cell penetrating peptide targeting GPR158 in GBM, which provide a novel delivery tool for GBM.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
PLOS ONE
● 5266 papers in training set
Top 18%
9.8%
Similar papers in this journal
2
Frontiers in Oncology
○ 103 papers in training set
Top 0.2%
9.7%
Similar papers in this journal
3
Frontiers in Pharmacology
○ 111 papers in training set
Top 0.4%
5.5%
Similar papers in this journal
4
Scientific Reports
○ 3612 papers in training set
Top 17%
5.2%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 28%
4.3%
Similar papers in this journal
6
Biomedicines
○ 67 papers in training set
Top 0.2%
4.0%
7
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 0.1%
3.4%
8
Pharmaceuticals
○ 34 papers in training set
Top 0.2%
3.2%
9
BioMed Research International
○ 28 papers in training set
Top 0.4%
3.2%
10
International Journal of Molecular Sciences
○ 494 papers in training set
Top 5%
2.4%
50% of probability mass above
11
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.4%
2.4%
12
Neoplasia
○ 23 papers in training set
Top 0.2%
2.4%
13
FEBS Open Bio
○ 31 papers in training set
Top 0.2%
2.1%
14
Aging
○ 75 papers in training set
Top 0.7%
2.1%
15
Molecules
○ 39 papers in training set
Top 0.5%
2.1%
16
Cancers
○ 213 papers in training set
Top 3%
1.5%
17
European Journal of Pharmacology
○ 15 papers in training set
Top 0.3%
1.4%
18
The Journal of Pharmacology and Experimental Therapeutics
○ 18 papers in training set
Top 0.3%
1.1%
19
Heliyon
○ 152 papers in training set
Top 5%
1.1%
20
Cancer Medicine
○ 26 papers in training set
Top 0.8%
1.1%
21
Journal of Nanobiotechnology
○ 14 papers in training set
Top 0.2%
1.0%
22
Life Sciences
○ 27 papers in training set
Top 0.9%
1.0%
23
RSC Advances
● 22 papers in training set
Top 0.7%
1.0%
24
Oncotarget
○ 18 papers in training set
Top 0.3%
1.0%
25
Antiviral Research
○ 50 papers in training set
Top 0.6%
1.0%
26
Cell Death & Disease
147 papers in training set
Top 3%
0.9%
27
Molecular Therapy
○ 81 papers in training set
Top 2%
0.9%
28
Cell Cycle
○ 17 papers in training set
Top 0.4%
0.8%
29
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.7%
0.8%
30
Theranostics
● 37 papers in training set
Top 1%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.